Introduction: The immune system can restrain or promote cancer development and growth.
Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the …

Introduction: Immunotherapy has recently come to the forefront of oncology treatment as a
potential means of combating cancer by restoring the body's adaptive cancer-immunity …

The era of immunotherapy has changed the face of how we approach treatment for many
oncologic and hematologic malignancies. Lung cancer has been in the forefront of …

Immunotherapy as a therapeutic strategy has seized the narrative throughout clinical
oncology over the past few years. Once considered a niche treatment for rare cancers …

Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1
monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its …

Introduction Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits
PD-L1: PD-1 and PD-L1: B7. 1 interactions, restoring anticancer immunity. Here, we report …

Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an
affirmed reality in the treatment of advanced non-small-cell lung cancer (NSCLC) patients …

Purpose: Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody that was
approved for metastatic non-small cell lung cancer (NSCLC) in patients with disease …

Immunotherapy is revolutionizing the treatment of non–small cell lung cancer (NSCLC).
Immune checkpoint inhibitors, including programmed cell death protein 1 (PD-1) and …

Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been
reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 …